Overview: Lamotrigine TestIntroduction: The Lamotrigine Test measures lamotrigine levels to monitor epilepsy treatment, preventing seizures. Aligned with 2023 AAN guidelines, it uses toxicology methods for high specificity, supporting drug monitoring. This test is critical for guiding treatment adjustments, ensuring therapeutic levels, and improving outcomes in toxicology for patients with epilepsy.
Other Names: Lamotrigine Assay, Epilepsy Drug Level Test.
FDA Status: Laboratory-developed test (LDT), meeting toxicology standards for diagnostic accuracy.
Historical Milestone: Lamotrigine testing began in the 1990s with epilepsy treatment research. Toxicology methods improved in the 2000s, enhancing precision.
Purpose: Measures lamotrigine levels to monitor epilepsy treatment, guides dosing, and prevents seizures.
Test Parameters: 1. Lamotrigine Level
Pretest Condition: No fasting required. Collect serum or plasma. Report history of seizures, epilepsy treatment, or medication adherence.
Specimen: Serum (SST, 2-5 mL), Plasma (EDTA, 2-4 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document seizures, epilepsy treatment, or medication side effects. Include current medications, especially other antiepileptics.
Consent: Written consent required, detailing the tests purpose, epilepsy treatment implications, and risks of blood collection.
Procedural Considerations: Uses toxicology methods to measure lamotrigine in serum or plasma. Results are available in 3-5 days, supporting treatment adjustments. Performed in laboratories, often for epilepsy management.
Factors Affecting Result Accuracy: Hemolysis, lipemia, or improper sample storage can affect results. Drug interactions may alter levels.
Clinical Significance: Therapeutic lamotrigine levels ensure seizure control, guiding dosing adjustments. Subtherapeutic or toxic levels require treatment modification.
Specialist Consultation: Consult a neurologist for result interpretation and treatment planning.
Additional Supporting Tests: EEG, other antiepileptic drug levels, or liver function tests to monitor epilepsy treatment.
Test Limitations: Drug interactions may affect levels; clinical correlation is needed. Timing of sample collection impacts results.
References: AAN Epilepsy Guidelines, 2023; Epilepsia, Kwan P, 2022.
